FOSUN PHARMA Subsidiary Receives Approval for Phase I Trial of HLX05-N Cancer Treatment

Stock News

04/14

FOSUN PHARMA (600196.SH) has announced that its subsidiary, Shanghai Henlius Biotech, along with its controlled subsidiaries, recently obtained approval from the National Medical Products Administration to conduct a Phase I clinical trial for HLX05-N, a recombinant anti-EGFR human-mouse chimeric monoclonal antibody injection, intended for the treatment of metastatic colorectal cancer. Henlius plans to initiate related clinical studies for this drug once conditions are met. HLX05-N is a biosimilar of cetuximab injection independently developed by the group and is intended for treating metastatic colorectal cancer and head and neck squamous cell carcinoma. As of March 2026, the group's cumulative R&D investment in HLX05-N amounts to approximately RMB 54 million (unaudited). According to the latest data from IQVIA MIDAS, global sales of cetuximab injection reached about USD 1.658 billion in 2025.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1125283237"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1125283237\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1125283237?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 17:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125283237","market":"sg","top_or_hot":-1,"title":"FOSUN PHARMA Subsidiary Receives Approval for Phase I Trial of HLX05-N Cancer Treatment","media":"Stock News","content":"<p>FOSUN PHARMA (600196.SH) has announced that its subsidiary, Shanghai Henlius Biotech, along with its controlled subsidiaries, recently obtained approval from the National Medical Products Administration to conduct a Phase I clinical trial for HLX05-N, a recombinant anti-EGFR human-mouse chimeric monoclonal antibody injection, intended for the treatment of metastatic colorectal cancer. Henlius plans to initiate related clinical studies for this drug once conditions are met. HLX05-N is a biosimilar of cetuximab injection independently developed by the group and is intended for treating metastatic colorectal cancer and head and neck squamous cell carcinoma. As of March 2026, the group's cumulative R&D investment in HLX05-N amounts to approximately RMB 54 million (unaudited). According to the latest data from IQVIA MIDAS, global sales of cetuximab injection reached about USD 1.658 billion in 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA Subsidiary Receives Approval for Phase I Trial of HLX05-N Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA Subsidiary Receives Approval for Phase I Trial of HLX05-N Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-14 17:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA (600196.SH) has announced that its subsidiary, Shanghai Henlius Biotech, along with its controlled subsidiaries, recently obtained approval from the National Medical Products Administration to conduct a Phase I clinical trial for HLX05-N, a recombinant anti-EGFR human-mouse chimeric monoclonal antibody injection, intended for the treatment of metastatic colorectal cancer. Henlius plans to initiate related clinical studies for this drug once conditions are met. HLX05-N is a biosimilar of cetuximab injection independently developed by the group and is intended for treating metastatic colorectal cancer and head and neck squamous cell carcinoma. As of March 2026, the group's cumulative R&D investment in HLX05-N amounts to approximately RMB 54 million (unaudited). According to the latest data from IQVIA MIDAS, global sales of cetuximab injection reached about USD 1.658 billion in 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"医美概念股","start_time":0,"source_url":"","article_id":"1125283237","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125283237","pubTimestamp":1776157835,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA (600196.SH) has announced that its subsidiary, Shanghai Henlius Biotech, along with its controlled subsidiaries, recently obtained approval from the National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK1593":"医美概念股","BK0239":"医药制造","BK0183":"MSCI概念","BK0196":"行业龙头","BK0060":"抗癌","BK0175":"白马股","BK0012":"证金概念","BK0187":"一线龙头","BK0028":"国家队","BK1515":"抗疫概念","BK0096":"民营医院","02196":"复星医药","BK1191":"制药","BK0188":"融资融券"},"translate_title":"复星医药子公司HLX05-N癌症治疗I期试验获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"FOSUN PHARMA (600196.SH) has announced that its subsidiary, Shanghai Henlius Biotech, along with its controlled subsidiaries, recently obtained approval from the National Medical Products Administration to conduct a Phase I clinical trial for HLX05-N, a recombinant anti-EGFR human-mouse chimeric monoclonal antibody injection, intended for the treatment of metastatic colorectal cancer. Henlius plans to initiate related clinical studies for this drug once conditions are met. HLX05-N is a biosimilar of cetuximab injection independently developed by the group and is intended for treating metastatic colorectal cancer and head and neck squamous cell carcinoma. As of March 2026, the group's cumulative R&D investment in HLX05-N amounts to approximately RMB 54 million (unaudited). According to the latest data from IQVIA MIDAS, global sales of cetuximab injection reached about USD 1.658 billion in 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}